Photo of Yevgeniy Semenov, MD, MA

Yevgeniy Semenov, MD, MA

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 724-6973
Fax: (617) 724-2745


ysemenov@mgh.harvard.edu

Photo of Yevgeniy Semenov, MD, MA

Massachusetts General Hospital
Phone: (617) 724-6973
Fax: (617) 724-2745


ysemenov@mgh.harvard.edu

Visualize Collaborations

Yevgeniy Semenov, MD, MA

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Assistant Professor, Dermatology, Harvard Medical School
  • Physician Investigator, Dermatology, Massachusetts General Hospital

HCC PROGRAM AFFILIATION

Research Abstract

Dr. Semenov's research aims to integrate large multi-modal clinical and molecular data from patients and tumor samples in developing algorithms and decision support models in cutaneous oncology. To support these efforts, Dr. Semenov has established a robust clinical program at MGH to support these efforts, where he holds an oncodermatology clinic within the Department of Dermatology and an intralesional immunotherapy clinic at the MGH Cancer Center. His research has resulted in important insights into the role of cutaneous immune-related adverse events (irAEs) as early prognostic biomarkers for immunotherapy response and patient survival, particularly in the setting of advanced-stage melanoma. Additionally, as a member of the Severe Immunotherapy Complications service at MGH, Dr. Semenov has been developing a multi-institutional clinical registry and biorepository for the study of immunotherapy toxicities.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Karagenova R, Lee E, Fuksman L, Mu A, Lu C, Lin C, Semenov YR. Nemolizumab for treatment-refractory cutaneous adverse events in patients with cancer: A retrospective multi-institutional case series. J Am Acad Dermatol 2026. PubMed
  • Lee E, Karagenova R, Fuksman L, Katyal P, Lim T, Sun V, Reynolds KL, Semenov YR. Evaluating the safety of Janus kinase inhibitors in the management of severe immune-related adverse events. J Immunother Cancer 2026. PubMed
  • Wan G, Nguyen N, Lu C, Khattab S, Yan B, Amadife M, Leung BW, Chen W, Rajeh A, Tang K, Thang C, Boland G, Reynolds KL, Yu KH, Gusev A, LeBoeuf NR, Kwatra SG, Semenov YR. Systemic Glucocorticoid Immunosuppression and Survival Among Immune Checkpoint Inhibitor Recipients. JAMA Netw Open 2026; 9:e2614323. PubMed
  • Rajeh A, Shahsavari S, Cornman H, Kollhoff A, Gupta A, Szeto MD, Kambala A, Oladipo OO, Parthasarathy V, Deng J, Marani M, Shahsavari S, Yossef SM, Vaddaraju V, Adawi W, Akiska YM, Gage DM, Wheelan S, Pritchard T, Kwatra MM, Semenov YR, Gusev A, Ho WJ, Yegnasubramanian S, Kwatra SG. Somatic mutations reveal hyperactive Notch signaling in prurigo nodularis. JCI Insight 2026. PubMed
  • Said JT, Li Y, Sadeghi N, Sullivan R, Lawrence D, Haugh A, Boland G, Cohen S, Buchbinder E, Liu D, Cornejo K, LeBoeuf NR, Semenov YR. Cutaneous Eruptions and Lifileucel/Interleukin 2 in Individuals With Metastatic Melanoma. JAMA Dermatol 2026. PubMed
  • Lu C, Cheng D, Mu A, Burke O, Fuksman L, Katyal P, Khattab S, Nguyen N, Beagles E, Chang C, Xu S, Hwang JC, Huhmann L, Starink N, Weinstock MA, Asgari MM, Hurlbert MS, Gaziano JM, Fillmore NR, Hartman RI, Semenov YR. Risk and Protective Factors for Uveal Melanoma: Evidence for a Protective Role of Autoimmune and Immune-mediated Conditions. J Am Acad Dermatol 2026. PubMed
  • Hwang JC, Huhmann LB, Cho K, Goryachev SD, Starink N, Weinstock MA, Asgari MM, Zheng C, Lu C, Feldman TC, Do NV, Gaziano JM, Semenov YR, Hurlbert MS, Fillmore NR, Hartman RI. Identification of Risk Factors for Acral Melanoma in US Veterans. JAMA Dermatol 2026. PubMed
  • Beagles E, Khattab S, Burke OM, Nguyen N, Chang C, Roster K, Rajeh A, Rashdan H, Moseley C, Yan B, Stagner AM, DeSimone M, Wan G, Semenov YR. The Impact of Clinicopathologic Features on the Prognosis of Thin Melanomas: A Retrospective Cohort Analysis. Br J Dermatol 2026. PubMed
  • Cheng D, Nguyen NTT, Thang CJ, Burke OM, LeBoeuf NR, Theodosakis N, Semenov YR. Exposure to intravenous immunoglobulin is associated with increased mortality in patients on immune checkpoint inhibitors: A population-based cohort study. JAAD Int 2025; 23:17-19. PubMed
  • Thang CJ, Duffy C, Khattab S, Semenov YR. The Current State and Future Prospects for Artificial Intelligence in Dermatology. Dermatol Clin 2025; 43:503-514. PubMed
  • Huang M, Wang D, Huang J, Bae AN, Xia Y, Zhao X, Mortaja M, Azin M, Collier MR, Semenov YR, Park JH, Demehri S. Hepatitis B virus promotes liver cancer by modulating the immune response to environmental carcinogens. Nat Commun 2025; 16:5360. PubMed
  • Khattab S, Wan G, Xu S, Moseley C, Tran M, Beagles E, Lin C, Leung BW, Azin M, Hao N, Reynolds KL, Demehri S, LeBoeuf NR, Semenov YR. Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events. J Immunother Cancer 2025. PubMed
  • Oskolas H, Nogueira FCN, Domont GB, Yu KH, Semenov YR, Sorger P, Steinfelder E, Corps L, Schulz L, Wieslander E, Fenyö D, Kárpáti S, Holló P, Kemény LV, Döme B, Megyesfalvi Z, Pawłowski K, Nishimura T, Kwon H, Encarnación-Guevara S, Szasz AM, Veréb Z, Gyulai R, Németh IB, Appelqvist R, Rezeli M, Baldetorp B, Horvatovich P, Malmström J, Pla I, Sanchez A, Knudsen B, Kiss A, Malm J, Marko-Varga G, Gil J. Comprehensive biobanking strategy with clinical impact at the European Cancer Moonshot Lund Center. 2025. PubMed
  • Hijaz BA, Braun N, Reynolds KL, Semenov YR, LeBoeuf NR, Chen ST. Nivolumab/relatlimab-associated cutaneous immune-related adverse events in patients treated for advanced melanoma: A multicenter retrospective cohort study. J Am Acad Dermatol 2025. PubMed
  • Oka T, Hasegawa T, Lee T, Oliver-Garcia VS, Mortaja M, Azin M, Horiba S, Smith SS, Khattab S, Trerice KE, Chen ST, Semenov YR, Demehri S. Langerhans Cells Directly Interact with Resident T Cells in the Human Epidermis. JID Innov 2025; 5:100324. PubMed
  • Khattab SY, Hijaz BA, Semenov YR. Cutaneous Imaging Techniques. Hematol Oncol Clin North Am 2024; 38:907-919. PubMed
  • Latoni DI, Semenov YR, Tsao H. Differential Time Series Analysis shows Decelerations in Melanoma Mortality Prior to the Widespread Use of Highly Effective Therapies. J Am Acad Dermatol 2024. PubMed
  • Latoni DI, Geller A, Semenov YR, Ji Z, Tsao H. Geotemporal analysis of melanoma incidence and mortality identifies distinct clusters of trends within the United States between 2001-2019. J Invest Dermatol 2024. PubMed
  • Rajeh A, Roster K, Nguyen N, Leung BW, Rashdan H, Semenov YR. Surgical margin reduction in excision of cutaneous melanoma: A retrospective analysis. 2024. PubMed
  • Park JH, Mortaja M, Son HG, Zhao X, Sloat LM, Azin M, Wang J, Collier MR, Tummala KS, Mandinova A, Bardeesy N, Semenov YR, Mino-Kenudson M, Demehri S. Statin prevents cancer development in chronic inflammation by blocking interleukin 33 expression. Nat Commun 2024; 15:4099. PubMed
  • Tang K, Rajeh A, Shaw KS, Nguyen N, Wan G, Hashemi KB, Castillo RL, Kwatra SG, LeBoeuf NR, Vleugels RA, Semenov YR. De novo autoimmune connective tissue disease and mortality in patients treated with anti-PD-1 and anti-PD-L1 therapy: a population-level cohort study. Br J Dermatol 2024. PubMed
  • Chen ST, Semenov YR, Alloo A, Bach DQ, Betof Warner A, Bougrine A, Burton L, Cappelli LC, Castells M, Cohen J, Dewan AK, Fadden R, Guggina L, Hegde A, Huang V, Johnson DB, Kaffenberger B, Kroshinsky D, Kwatra S, Kwong B, Lacouture ME, Larocca C, Leventhal J, Markova A, McDunn J, Mooradian MJ, Naidoo J, Choi J, Nambudiri V, Nelson CA, Patel AB, Pimkina J, Rine J, Rubin KM, Sauder M, Shaigany S, Shariff A, Sullivan RJ, Zubiri L, Reynolds KL, LeBoeuf NR. Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy. J Immunother Cancer 2024. PubMed
  • Wan G, Maliga Z, Yan B, Vallius T, Shi Y, Khattab S, Chang C, Nirmal AJ, Yu KH, Liu D, Lian CG, DeSimone MS, Sorger PK, Semenov YR. SpatialCells: automated profiling of tumor microenvironments with spatially resolved multiplexed single-cell data. 2024. PubMed
  • Rashdan H, Adamson A, Semenov YR. Adjuvant Immunotherapy in Stage II Melanoma-Further Risk Stratification is Needed. JAMA Dermatol 2024. PubMed
  • Wan G, Khattab S, Leung BW, Zhang S, Nguyen N, Tran M, Lin C, Chang C, Alexander N, Jairath R, Phillipps J, Tang K, Rajeh A, Zubiri L, Chen ST, Demehri S, Yu KH, Gusev A, Kwatra SG, LeBoeuf NR, Reynolds KL, Semenov YR. Cancer Type and Histology Influence Cutaneous Immunotherapy Toxicities: A Multi-Institutional Cohort Study. Br J Dermatol 2024. PubMed
  • Reardon RM, Perlman KL, Asdourian MS, Shah N, Jacoby TV, Thompson LL, Reynolds KL, Semenov YR, Chen ST. Associations between dermatologic immune-related adverse event morphologies and systemic immunomodulatory/immunosuppressive treatment: A large retrospective cohort study. J Am Acad Dermatol 2024. PubMed
  • Rashdan H, Zhang S, Wan G, Nguyen N, Roster K, Rajeh A, Tang K, Chen W, Moseley C, Chen S, LeBoeuf N, Semenov YR. Timing of cutaneous immune-related adverse events impacts survival in patients with cancer treated with immune-checkpoint inhibitors: A multi-institutional cohort study. J Am Acad Dermatol 2024. PubMed
  • Le TK, Newland ES, Brown I, Goldberg R, Semenov YR, Kwatra SG. Cutaneous Immune-Related Adverse Event Burden and Effect on Immunotherapy: A Retrospective Review of the Experience at a Tertiary Care Immunotherapy Center. J Am Acad Dermatol 2023. PubMed
  • Shaw KS, Nguyen TT, Rajeh A, Cohen SM, Semenov YR, Reusch DB, Dedeoglu F, Vleugels RA, Ganske IM. Use of 3-Dimensional Stereophotogrammetry to Detect Disease Progression in Craniofacial Morphea. JAMA Dermatol 2023; 159:1232-1239. PubMed
  • Wan G, Nguyen N, Leung BW, Rashdan H, Tang K, Roster K, Collier MR, Ugwu-Dike PO, Raval NS, Alexander NA, Jairath R, Phillipps J, Amadife M, Zhang S, Gusev A, Chen ST, Reynolds KL, LeBoeuf NR, Kwatra SG, Semenov YR. Pre-existing inflammatory disease predicts cutaneous immunotherapy toxicity development: A multi-institutional cohort study. J Am Acad Dermatol 2023. PubMed
  • Wan G, Leung BW, DeSimone MS, Nguyen N, Rajeh A, Collier MR, Rashdan H, Roster K, Zhou X, Moseley CB, Nirmal AJ, Pelletier RJ, Maliga Z, Marko-Varga G, Németh IB, Tsao H, Asgari MM, Gusev A, Stagner AM, Lian CG, Hurlbert MS, Liu F, Yu KH, Sorger PK, Semenov YR. Development and validation of time-to-event models to predict metastatic recurrence of localized cutaneous melanoma. J Am Acad Dermatol 2023. PubMed
  • Roster K, Rajeh A, Nguyen N, Tang K, Zhang S, Rashdan H, Wan G, Leung BW, Khattab S, Chen S, LeBoeuf NR, Semenov YR. Checkpoint Inhibitor Antibody Type Influences the Development of Cutaneous Immune-Related Adverse Events: A Multi-institutional Study. J Am Acad Dermatol 2023. PubMed
  • Allais BS, Fay CJ, Kim DY, Semenov YR, LeBoeuf NR. Cutaneous immune-related adverse events from immune checkpoint inhibitor therapy: Moving beyond "maculopapular rash". Immunol Rev 2023; 318:22-36. PubMed
  • Roster K, Rajeh A, Wu F, Wan G, Thang C, Rashdan H, Nguyen N, Semenov YR. Recurrence and survival in early-stage acral lentiginous melanoma: A retrospective analysis. J Am Acad Dermatol 2023. PubMed
  • Leung BW, Wan G, Nguyen N, Rashdan H, Zhang S, Chen W, Cohen S, Boland GM, Sullivan RJ, Fadden RM, Kaufman HL, Kwatra SG, LeBoeuf NR, Semenov YR. Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study. J Am Acad Dermatol 2023; 88:1265-1270. PubMed
  • Rajeh A, Wan G, Roster K, Rashdan H, Seo J, Nguyen N, Collier MR, Leung BW, Semenov YR. Underuse of sentinel lymph node biopsy for early-stage melanoma. J Am Acad Dermatol 2023. PubMed
  • Wan G, Leung B, Nguyen N, DeSimone MS, Liu F, Choi MS, Ho D, Laucks V, Duey S, Sullivan RJ, Boland GM, LeBoeuf NR, Liu D, Gusev A, Kwatra SG, Sorger PK, Yu KH, Semenov YR. The impact of stage-related features in melanoma recurrence prediction: A machine learning approach. JAAD Int 2023; 10:28-30. PubMed
  • Stephens MR, Asdourian MS, Jacoby TV, Shah N, Thompson LL, Otto T, Semenov YR, Reynolds KL, Sullivan RJ, Foreman RK, Chen ST. Tumor-infiltrating lymphocytes as a predictive biomarker of cutaneous immune-related adverse events after immune checkpoint blockade in patients with advanced melanoma. J Am Acad Dermatol 2023. PubMed
  • Leung BW, Collier MR, Tiu BC, Wan G, Nguyen N, Tang K, Zhang S, Chen W, Chen ST, LeBoeuf NR, Semenov YR. Patterns in utilization of health care services and medications among patients with cutaneous immune-related adverse events: A population-level cohort study. J Am Acad Dermatol 2023. PubMed
  • Asdourian MS, Jacoby TV, Shah N, Otto T, Thompson LL, Dee EC, Reynolds KL, Semenov YR, Chen ST. Non-cutaneous immune-related adverse events predict overall and progression-free survival in patients with cutaneous toxicities after immune checkpoint inhibitor therapy. J Am Acad Dermatol 2023. PubMed
  • Chen W, Wan G, Nguyen N, Leung B, Wen J, Collier MR, Kwatra SG, Semenov YR. Identification of cutaneous immune-related adverse events by International Classification of Diseases codes and medication administration. JAAD Int 2022; 9:112-115. PubMed
  • Wan G, Nguyen N, Liu F, DeSimone MS, Leung BW, Rajeh A, Collier MR, Choi MS, Amadife M, Tang K, Zhang S, Phillipps JS, Jairath R, Alexander NA, Hua Y, Jiao M, Chen W, Ho D, Duey S, Németh IB, Marko-Varga G, Valdés JG, Liu D, Boland GM, Gusev A, Sorger PK, Yu KH, Semenov YR. Prediction of early-stage melanoma recurrence using clinical and histopathologic features. NPJ Precis Oncol 2022; 6:79. PubMed
  • Sutaria N, Alphonse MP, Roh YS, Choi J, Parthasarathy V, Deng J, Bordeaux ZA, Taylor MT, Pritchard T, Kim N, Aguh C, Semenov YR, Archer NK, Garza LA, Kang S, Kwatra SG. Cutaneous Transcriptomics Identifies Fibroproliferative and Neurovascular Gene Dysregulation in Prurigo Nodularis Compared with Psoriasis and Atopic Dermatitis. J Invest Dermatol 2022; 142:2537-2540. PubMed
  • Asdourian MS, Shah N, Jacoby TV, Semenov YR, Otto T, Thompson LL, Dee EC, Reynolds KL, Chen ST. Development of multiple cutaneous immune-related adverse events among cancer patients after immune checkpoint blockade. J Am Acad Dermatol 2022. PubMed
  • Asdourian MS, Jacoby TV, Shah N, Thompson LL, Otto T, Semenov YR, LeBoeuf NR, Reynolds KL, Dewan AK, Chen ST. Morphologic characteristics of cutaneous immune-related adverse events in patients receiving immune checkpoint inhibitors combined with other anti-cancer therapies: a multicenter retrospective study. J Am Acad Dermatol 2022. PubMed
  • Tiu BC, Zubiri L, Iheke J, Pahalyants V, Theodosakis N, Ugwu-Dike P, Seo J, Tang K, Sise ME, Sullivan R, Naidoo J, Mooradian MJ, Semenov YR, Reynolds KL. Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study. J Immunother Cancer 2022. PubMed
  • Le TK, Brown I, Goldberg R, Taylor MT, Deng J, Parthasarathy V, Bordeaux ZA, Alphonse MP, Kwatra MM, Naranbhai V, Gusev A, Alhariri J, LeBoeuf NR, Reynolds KL, Cappelli LC, Naidoo J, Brahmer JR, Kang S, Semenov YR, Kwatra SG. Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study. J Invest Dermatol 2022. PubMed
  • Asdourian MS, Shah N, Jacoby TV, Thompson LL, Otto T, Semenov YR, Reynolds KL, Chen ST. Evaluating patterns of co-occurrence between cutaneous and noncutaneous immune-related adverse events after immune checkpoint inhibitor therapy. J Am Acad Dermatol 2022. PubMed
  • Le TK, Kaul S, Cappelli LC, Naidoo J, Semenov YR, Kwatra SG. Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses. J Dermatolog Treat 2022; 33:1691-1695. PubMed
  • Pahalyants V, Murphy WS, Klebanov N, Lu C, Theodosakis N, Klevens MR, Estiri H, Lilly E, Asgari M, Semenov YR. Reply to: "COVID-19 vaccination in IMID patients receiving rituximab: A personalized regimen should be formulated". J Am Acad Dermatol 2022. PubMed
  • Tang K, Tiu BC, Wan G, Zhang S, Nguyen N, Leung B, Gusev A, Reynolds KL, Kwatra SG, Semenov YR. Pre-Existing Autoimmune Disease and Mortality in Patients Treated With Anti-PD-1 and Anti-PD-L1 Therapy. Journal of the National Cancer Institute 2022. PubMed
  • Asdourian MS, Otto TS, Jacoby TV, Shah N, Thompson LL, Blum SM, Reynolds KL, Semenov YR, Lawrence DP, Sullivan RJ, Boland GM, Villani AC, Chen ST. Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanoma. J Am Acad Dermatol 2022. PubMed
  • Sutaria N, Marani M, Choi J, Roh YS, Parthasarathy V, Deng J, Bordeaux ZA, Taylor MT, Lee KK, Pritchard T, Alajmi A, Adawi W, Semenov YR, Alphonse MP, Kwatra SG. Racial differences in dysregulation of the renin-angiotensin-aldosterone system in patients with prurigo nodularis. J. Dermatol. Sci. 2022; 105:130-136. PubMed
  • Said JT, Liu M, Talia J, Singer SB, Semenov YR, Wei EX, Mostaghimi A, Nelson CA, Giobbie-Hurder A, LeBoeuf NR. Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors. JAMA Dermatol 2022; 158:552-557. PubMed
  • Tang K, Seo J, Tiu BC, Le TK, Pahalyants V, Raval NS, Ugwu-Dike PO, Zubiri L, Naranbhai V, Carrington M, Gusev A, Reynolds KL, LeBoeuf NR, Asgari MM, Kwatra SG, Semenov YR. Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy. JAMA Dermatol 2022; 158:189-193. PubMed
  • Choi J, Sutaria N, Roh YS, Bordeaux Z, Sweren RJ, Semenov YR, Kwatra SG. Racial and ethnic disparities in inpatient health care utilization for mycosis fungoides: A cross-sectional analysis of the 2012-2017 National Inpatient Sample. J Am Acad Dermatol 2022; 86:1408-1410. PubMed
  • Sutaria N, Adawi W, Brown I, Parthasarathy V, Roh YS, Choi J, Bordeaux ZA, Trinh P, Le TK, Deng J, Semenov YR, Kwatra SG. Racial disparities in mortality among patients with prurigo nodularis: A multi-center cohort study. J Am Acad Dermatol 2022; 86:487-490. PubMed
  • Roh YS, Marani M, Choi U, Sutaria N, Parthasarathy V, Deng J, Bordeaux ZA, Taylor MT, Semenov YR, Kwatra SG. Validation of International Classification of Diseases Tenth Revision code for prurigo nodularis. J Am Acad Dermatol 2022; 87:482-484. PubMed
  • Sutaria N, Alphonse MP, Marani M, Parthasarathy V, Deng J, Wongvibulsin S, Williams K, Roh YS, Choi J, Bordeaux Z, Pritchard T, Dillen C, Semenov YR, Kwatra MM, Archer NK, Garza LA, Dong X, Kang S, Kwatra SG. Cluster Analysis of Circulating Plasma Biomarkers in Prurigo Nodularis Reveals a Distinct Systemic Inflammatory Signature in African Americans. J Invest Dermatol 2022; 142:1300-1308.e3. PubMed
  • Deng J, Parthasarathy V, Adawi W, Bordeaux Z, Sutaria N, Gami A, Taylor M, Lee KK, Marani M, Brown I, Kambala A, Cornman HL, Alajmi A, Pritchard T, Oladipo OO, Semenov YR, Kwatra SG. Risk of Hematologic Cancer in Patients With Undifferentiated Pruritus. JAMA Dermatol 2022; 158:791-795. PubMed
  • Wongvibulsin S, Parthasarathy V, Pahalyants V, Murphy W, Sutaria N, Roh YS, Bordeaux ZA, Deng J, Taylor MT, Semenov YR, Kwatra SG. Latent class analysis identification of prurigo nodularis comorbidity phenotypes. Br J Dermatol 2022; 186:903-905. PubMed
  • Sutaria N, Semenov YR, Kwatra SG. Understanding racial disparities in prurigo nodularis. J Am Acad Dermatol 2022; 87:e111-e112. PubMed
  • Gil J, Rezeli M, Lutz EG, Kim Y, Sugihara Y, Malm J, Semenov YR, Yu KH, Nguyen N, Wan G, Kemény LV, Kárpáti S, Németh IB, Marko-Varga G. An Observational Study on the Molecular Profiling of Primary Melanomas Reveals a Progression Dependence on Mitochondrial Activation. Cancers (Basel) 2021. PubMed
  • Raval NS, Hodges WT, Ugwu-Dike PO, Godoy F, Ansstas G, Cornelius LA, Musiek AC, Asgari MM, Semenov YR. Racial and socioeconomic differences in acral lentiginous melanoma outcomes: A Surveillance, Epidemiology, and End Results analysis. J Am Acad Dermatol 2021. PubMed
  • Pahalyants V, Murphy WS, Klebanov N, Lu C, Theodosakis N, Klevens RM, Estir H, Lilly E, Asgari M, Semenov YR. Immunosuppressive biologics did not increase the risk of COVID-19 or subsequent mortality: a retrospective matched cohort study from Massachusetts. J Am Acad Dermatol 2021. PubMed
  • Rosenberg AR, Weston SJ, Deshields T, Fields RC, Linette GP, Cornelius LA, Semenov YR. Health-related quality of life in patients with malignant melanoma by stage and treatment status. J Am Acad Dermatol 2021; 85:486-489. PubMed
  • Estiri H, Strasser ZH, Brat GA, Semenov YR, , Patel CJ, Murphy SN. Evolving Phenotypes of non-hospitalized Patients that Indicate Long Covid. medRxiv 2021. PubMed
  • Phelan PS, Semenov YR, Nahmias ZP. Worldwide seasonal variation in search volume for cutaneous warts from 2004 to 2019. J Am Acad Dermatol 2021; 84:1417-1419. PubMed
  • Wongvibulsin S, Pahalyants V, Kalinich M, Murphy W, Yu KH, Wang F, Chen ST, Reynolds K, Kwatra SG, Semenov YR. Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis. J Am Acad Dermatol 2021. PubMed
  • Molina GE, Zubiri L, Cohen JV, Durbin SM, Petrillo L, Allen IM, Murciano-Goroff YR, Dougan M, Thomas MF, Faje AT, Rengarajan M, Guidon AC, Chen ST, Okin D, Medoff BD, Nasrallah M, Kohler MJ, Schoenfeld SR, Karp Leaf RS, Sise ME, Neilan TG, Zlotoff DA, Farmer JR, Mooradian MJ, Bardia A, Mai M, Sullivan RJ, Semenov YR, Villani AC, Reynolds KL. Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. Oncologist 2021. PubMed
  • Kalinich M, Murphy W, Wongvibulsin S, Pahalyants V, Yu KH, Lu C, Wang F, Zubiri L, Naranbhai V, Gusev A, Kwatra SG, Reynolds KL, Semenov YR. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA. J Immunother Cancer 2021. PubMed
  • Osemwota O, Herbosa CM, Zhong C, Kwatra SG, Kim BS, Semenov YR. Ethnic variations in scalp pruritus and hair loss. J Am Acad Dermatol 2021; 84:792-794. PubMed
  • Estiri H, Strasser ZH, Brat GA, Semenov YR, , Patel CJ, Murphy SN. Evolving phenotypes of non-hospitalized patients that indicate long COVID. BMC Med 2021; 19:249. PubMed
  • Semenov YR, Herbosa CM, Rogers AT, Huang A, Kwatra SG, Cohen B, Anadkat MJ, Silverberg JI. Psoriasis and mortality in the United States: Data from the National Health and Nutrition Examination Survey. J Am Acad Dermatol 2021; 85:396-403. PubMed
  • Zubiri L, Molina GE, Mooradian MJ, Cohen J, Durbin SM, Petrillo L, Boland GM, Juric D, Dougan M, Thomas MF, Faje AT, Rengarajan M, Guidon AC, Chen ST, Okin D, Medoff BD, Nasrallah M, Kohler MJ, Schoenfeld SR, Karp-Leaf RS, Sise ME, Neilan TG, Zlotoff DA, Farmer JR, Bardia A, Sullivan RJ, Blum SM, Semenov YR, Villani AC, Reynolds KL. Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. J Immunother Cancer 2021. PubMed
  • Zhang J, Erickson S, Semenov YR, Council ML. Surgical Outcomes and Risk Factors for Apical Triangle Basal Cell Carcinomas: A Single Institution Analysis. Dermatol Surg 2021; 47:1125-1127. PubMed
  • Klebanov N, Pahalyants V, Murphy WS, Theodosakis N, Zubiri L, Klevens RM, Kwatra SG, Lilly E, Reynolds KL, Semenov YR. Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors. Oncologist 2021; 26:e898-e901. PubMed
  • Gusev A, Groha S, Taraszka K, Semenov YR, Zaitlen N. Constructing germline research cohorts from the discarded reads of clinical tumor sequences. Genome Med 2021; 13:179. PubMed
  • Wongvibulsin S, Sutaria N, Williams KA, Huang AH, Choi J, Roh YS, Hong M, Kelley D, Pahalyants V, Murphy W, Alphonse MP, Bakhshi P, Walia A, Semenov YR, Kwatra SG. A Nationwide Study of Prurigo Nodularis: Disease Burden and Healthcare Utilization in the United States. J Invest Dermatol 2021; 141:2530-2533.e1. PubMed
  • Herbosa CM, Bhat TS, Semenov YR, Rosman IS, Musiek AC. Diagnostic concordance of clinical diagnosis, tissue culture, and histopathology testing for skin and soft tissue infections: A single-center retrospective study. Int J Womens Dermatol 2020; 6:395-398. PubMed
  • Kwatra SG, Hines H, Semenov YR, Trotter SC, Holland E, Leachman S. A Dermatologist's Guide to Implementation of Gene Expression Profiling in the Management of Melanoma. J Clin Aesthet Dermatol 2020; 13:s3-s14. PubMed
  • Almazan E, Roh YS, Belzberg M, Qin CX, Williams K, Choi J, Sutaria N, Kaffenberger B, Semenov YR, Alhariri J, Kwatra SG. Comorbidities Associated with Granuloma Annulare: A Cross-Sectional, Case-Control Study. Medicines (Basel) 2020. PubMed
  • Bigelow RT, Semenov YR, Hoffman HJ, Agrawal Y. Association between vertigo, cognitive and psychiatric conditions in US children: 2012 National Health Interview Survey. Int. J. Pediatr. Otorhinolaryngol. 2020; 130:109802. PubMed
  • Kwatra SG, Boozalis E, Huang AH, Nanni C, Khanna R, Williams KA, Semenov YR, Roberts CM, Burns RF, Krischak M, Kwatra MM. Proteomic and Phosphoproteomic Analysis Reveals that Neurokinin-1 Receptor (NK1R) Blockade with Aprepitant in Human Keratinocytes Activates a Distinct Subdomain of EGFR Signaling: Implications for the Anti-Pruritic Activity of NK1R Antagonists. Medicines (Basel) 2019. PubMed
  • Huang AH, Kwatra SG, Khanna R, Semenov YR, Okoye GA, Sweren RJ. Racial Disparities in the Clinical Presentation and Prognosis of Patients with Mycosis Fungoides. J Natl Med Assoc 2019; 111:633-639. PubMed
  • Semenov YR, Hsiang EY, Huang A, Herbosa CM, Hui X, Kwatra SG, Cohen B, Anadkat MJ. Association Between Psoriasis with Arthritis and Hearing Impairment in US Adults: Data from the National Health and Nutrition Examination Survey. J Rheumatol 2019; 46:587-594. PubMed
  • Boozalis E, Tang O, Patel S, Semenov YR, Pereira MP, Stander S, Kang S, Kwatra SG. Ethnic differences and comorbidities of 909 prurigo nodularis patients. J Am Acad Dermatol 2018; 79:714-719.e3. PubMed
  • Boozalis E, Semenov YR, Kwatra SG. Food and drug administration approval process for dermatology drugs in the United States. J Dermatolog Treat 2018; 29:536-538. PubMed
  • Rogers AT, Semenov YR, Kwatra SG, Okoye GA. Racial disparities in the management of acne: evidence from the National Ambulatory Medical Care Survey, 2005-2014. J Dermatolog Treat 2018; 29:287-289. PubMed
  • Agrawal Y, Pineault KG, Semenov YR. Health-related quality of life and economic burden of vestibular loss in older adults. Laryngoscope Investig Otolaryngol 2018; 3:8-15. PubMed
  • Grandhi R, He A, Semenov YR, Kwatra SG. Seasonal variation of itch: A study using real-time data from 2004 to 2016. J Am Acad Dermatol 2017; 76:563-564. PubMed
  • Crowson MG, Semenov YR, Tucci DL, Niparko JK. Quality of Life and Cost-Effectiveness of Cochlear Implants: A Narrative Review. Audiol. Neurootol. 2017; 22:236-258. PubMed
  • Bigelow RT, Semenov YR, Anson E, du Lac S, Ferrucci L, Agrawal Y. Impaired Vestibular Function and Low Bone Mineral Density: Data from the Baltimore Longitudinal Study of Aging. J Assoc Res Otolaryngol 2016; 17:433-40. PubMed
  • Bigelow RT, Semenov YR, du Lac S, Hoffman HJ, Agrawal Y. Vestibular vertigo and comorbid cognitive and psychiatric impairment: the 2008 National Health Interview Survey. J Neurol Neurosurg Psychiatry 2016; 87:367-72. PubMed
  • Semenov YR, Bigelow RT, Xue QL, du Lac S, Agrawal Y. Association Between Vestibular and Cognitive Function in U.S. Adults: Data From the National Health and Nutrition Examination Survey. J Gerontol A Biol Sci Med Sci 2016; 71:243-50. PubMed
  • Harun A, Clark J, Semenov YR, Francis HW. The Role of Obliteration in the Achievement of a Dry Mastoid Bowl. Otol. Neurotol. 2015; 36:1510-7. PubMed
  • Bigelow RT, Semenov YR, Trevino C, Ferrucci L, Resnick SM, Simonsick EM, Xue QL, Agrawal Y. Association Between Visuospatial Ability and Vestibular Function in the Baltimore Longitudinal Study of Aging. J Am Geriatr Soc 2015; 63:1837-44. PubMed
  • Sun DQ, Ward BK, Semenov YR, Carey JP, Della Santina CC. Bilateral Vestibular Deficiency: Quality of Life and Economic Implications. JAMA Otolaryngol Head Neck Surg 2014; 140:527-34. PubMed
  • Chan JY, Semenov YR, Gourin CG. Postoperative urinary tract infection and short-term outcomes and costs in head and neck cancer surgery. 2013; 148:602-10. PubMed
  • Hennessey P, Semenov YR, Gourin CG. The effect of deep venous thrombosis on short-term outcomes and cost of care after head and neck cancer surgery. Laryngoscope 2012; 122:2199-204. PubMed
  • Semenov YR, Martinez-Monedero R, Niparko JK. Cochlear implants: clinical and societal outcomes. Otolaryngol. Clin. North Am. 2012; 45:959-81. PubMed
  • Semenov YR, Starmer HM, Gourin CG. The effect of pneumonia on short-term outcomes and cost of care after head and neck cancer surgery. Laryngoscope 2012; 122:1994-2004. PubMed
  • Semenov YR, Yeh ST, Seshamani M, Wang NY, Tobey EA, Eisenberg LS, Quittner AL, Frick KD, Niparko JK, . Age-dependent cost-utility of pediatric cochlear implantation. ; 34:402-12. PubMed
  • Harun A, Semenov YR, Agrawal Y. Vestibular Function and Activities of Daily Living: Analysis of the 1999 to 2004 National Health and Nutrition Examination Surveys. Gerontol Geriatr Med . PubMed
Hide
Visualize Collaborations